Capricor Therapeutics (CAPR)
(Delayed Data from NSDQ)
$7.67 USD
-0.01 (-0.13%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $7.67 0.00 (0.00%) 6:08 PM ET
4-Sell of 5 4
F Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CAPR 7.67 -0.01(-0.13%)
Will CAPR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CAPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CAPR
FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks
Capricor (CAPR) Moves 20.4% Higher: Will This Strength Last?
CAPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates
QuidelOrtho (QDEL) Q4 Earnings and Revenues Top Estimates
Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?
Other News for CAPR
Biotech stocks rise following Prasad exit from FDA
12 Health Care Stocks Moving In Wednesday's Intraday Session
Capricor Therapeutics (CAPR) Sees Increased Bullish Options Activity
Capricor Therapeutics call volume above normal and directionally bullish
Biotech stocks rise following Prasad exit from FDA